Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors

References

• Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785–97. doi:10.1038/ni.1923. PMID:20720586
   PubMed Web of Science ®Google Scholar
• Ehrengruber MU, Geiser T, Deranleau DA. Activation of human neutrophils by C3a and C5A. Comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst. FEBS Lett. 1994;346(2-3):181–4. doi:10.1016/0014-5793(94)00463-3. PMID:8013630
   PubMed Web of Science ®Google Scholar
• Ali H. Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a. Immunol Lett. 2010;128(1):36–45. doi:10.1016/j.imlet.2009.10.007. PMID:19895849
   PubMed Web of Science ®Google Scholar
• Cavaillon JM, Fitting C, Haeffner-Cavaillon N. Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol. 1990;20(2):253–7. doi:10.1002/eji.1830200204. PMID:1690130
   PubMed Web of Science ®Google Scholar
• Ward PA, Newman LJ. A neutrophil chemotactic factor from human C'5. J Immunol. 1969;102(1):93–9. PMID:5765461
   PubMed Web of Science ®Google Scholar
• DiScipio RG, Schraufstatter IU. The role of the complement anaphylatoxins in the recruitment of eosinophils. Int Immunopharmacol. 2007;7(14):1909–23. doi:10.1016/j.intimp.2007.07.006. PMID:18039528
   PubMed Web of Science ®Google Scholar
• Hartmann K, Henz BM, Krüger-Krasagakes S, Köhl J, Burger R, Guhl S, Haase I, Lippert U, Zuberbier T. C3a and C5a stimulate chemotaxis of human mast cells. Blood. 1997;89(8):2863–70. PMID:9108406
   PubMed Web of Science ®Google Scholar
• Morgan BP, Walters D, Serna M, Bubeck D. Terminal complexes of the complement system: new structural insights and their relevance to function. Immunol Rev. 2016;274(1):141–51.
   PubMed Web of Science ®Google Scholar
• Müller-Eberhard HJ. The killer molecule of complement. J Invest Dermatol. 1985;85(1 Suppl):47s–52s. doi:10.1111/1523-1747.ep12275445. PMID:3891882
   PubMed Web of Science ®Google Scholar
• Tegla CA, Cudrici C, Patel S, Trippe R 3rd, Rus V, Niculescu F, Rus H. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res. 2011;51(1):45–60. doi:10.1007/s12026-011-8239-5. PMID:21850539
   PubMed Web of Science ®Google Scholar
• Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature. 1991;349(6310):614–7. doi:10.1038/349614a0. PMID:1847994
   PubMed Web of Science ®Google Scholar
• Monk PN, Scola AM, Madala P, Fairlie DP. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol. 2007;152(4):429–48. doi:10.1038/sj.bjp.0707332. PMID:17603557
   PubMed Web of Science ®Google Scholar
• Matthews KW, Mueller-Ortiz SL, Wetsel RA. Carboxypeptidase N: a pleiotropic regulator of inflammation. Mol Immunol. 2004;40(11):785–93. doi:10.1016/j.molimm.2003.10.002. PMID:14687935
   PubMed Web of Science ®Google Scholar
• Fernandez HN, Hugli TE. Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a. J Biol Chem. 1978;253(19):6955–64. PMID:690134
   PubMed Web of Science ®Google Scholar
• Fernandez HN, Henson PM, Otani A, Hugli TE. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol. 1978;120(1):109–15. PMID:342601
   PubMed Web of Science ®Google Scholar
• Ohno M, Hirata T, Enomoto M, Araki T, Ishimaru H, Takahashi TA. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol Immunol. 2000;37(8):407–12. doi:10.1016/S0161-5890(00)00067-5. PMID:11090875
   PubMed Web of Science ®Google Scholar
• Bamberg CE, Mackay CR, Lee H, Zahra D, Jackson J, Lim YS, Whitfeld PL, Craig S, Corsini E, Lu B, Gerard C, Gerard NP. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem. 2010;285(10):7633–44. doi:10.1074/jbc.M109.092106. PMID:20044484
   PubMed Web of Science ®Google Scholar
• Croker DE, Halai R, Kaeslin G, Wende E, Fehlhaber B, Klos A, Monk PN, Cooper MA. C5aR2 can modulate ERK1/2 signaling in macrophages via heteromer formation with C5aR1 and beta-arrestin recruitment. Immunol Cell Biol. 2014;92(7):631–9. doi:10.1038/icb.2014.32. PMID:24777312
   PubMed Web of Science ®Google Scholar
• Wang R, Lu B, Gerard C, Gerard NP. Disruption of the complement anaphylatoxin receptor C5L2 exacerbates inflammation in allergic contact dermatitis. J Immunol. 2013;191(8):4001–9. doi:10.4049/jimmunol.1301626. PMID:24043888
   PubMed Web of Science ®Google Scholar
• Gerard NP, Lu B, Liu P, Craig S, Fujiwara Y, Okinaga S, Gerard C. An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J Biol Chem. 2005;280(48):39677–80. doi:10.1074/jbc.C500287200. PMID:16204243
   PubMed Web of Science ®Google Scholar
• Zhang X, Schmudde I, Laumonnier Y, Pandey MK, Clark JR, König P, Gerard NP, Gerard C, Wills-Karp M, Köhl J. A critical role for C5L2 in the pathogenesis of experimental allergic asthma. J Immunol. 2010;185(11):6741–52. doi:10.4049/jimmunol.1000892. PMID:20974988
   PubMed Web of Science ®Google Scholar
• Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, Penfold ME, Gan L, Hu P, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014;25(2):225–31. doi:10.1681/ASN.2013020143. PMID:24179165
   PubMed Web of Science ®Google Scholar
• Hsu WC, Yang FC, Lin CH, Hsieh SL, Chen NJ. C5L2 is required for C5a-triggered receptor internalization and ERK signaling. Cell Signal. 2014;26(7):1409–19. doi:10.1016/j.cellsig.2014.02.021. PMID:24631530
   PubMed Web of Science ®Google Scholar
• Chen NJ, Mirtsos C, Suh D, Lu YC, Lin WJ, McKerlie C, Lee T, Baribault H, Tian H, Yeh WC. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature. 2007;446(7132):203–7. doi:10.1038/nature05559. PMID:17322907
   PubMed Web of Science ®Google Scholar
• Bosmann M, Grailer JJ, Ruemmler R, Russkamp NF, Zetoune FS, Sarma JV, Standiford TJ, Ward PA. Extracellular histones are essential effectors of C5aR- and C5L2-mediated tissue damage and inflammation in acute lung injury. FASEB J. 2013;27(12):5010–21. doi:10.1096/fj.13-236380. PMID:23982144
   PubMed Web of Science ®Google Scholar
• Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M, Mackay CR, Zetoune FS, Gerard NP, Cianflone K, Köhl J, et al. Functional roles for C5a receptors in sepsis. Nat Med. 2008;14(5):551–7. doi:10.1038/nm1753. PMID:18454156
   PubMed Web of Science ®Google Scholar
• Poppelaars F, van Werkhoven MB, Kotimaa J, Veldhuis ZJ, Ausema A, Broeren SGM, Damman J, Hempel JC, Leuvenink HGD, Daha MR et al. Critical role for complement receptor C5aR2 in the pathogenesis of renal ischemia-reperfusion injury. FASEB J. 2017;31(7):3193–3204. doi:10.1096/fj.201601218R. PMID:28396344
   PubMed Web of Science ®Google Scholar
• Cain SA, Monk PN. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J Biol Chem. 2002;277(9):7165–9. doi:10.1074/jbc.C100714200. PMID:11773063
   PubMed Web of Science ®Google Scholar
• Zuiderweg ER, Nettesheim DG, Mollison KW, Carter GW. Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data. Biochemistry. 1989;28(1):172–85. doi:10.1021/bi00427a025. PMID:2784981
   PubMed Web of Science ®Google Scholar
• Zhang X, Boyar W, Toth MJ, Wennogle L, Gonnella NC. Structural definition of the C5a C terminus by two-dimensional nuclear magnetic resonance spectroscopy. Proteins. 1997;28(2):261–7. doi:10.1002/(SICI)1097-0134(199706)28:2%3c261::AID-PROT13%3e3.0.CO;2-G. PMID:9188742
   PubMed Web of Science ®Google Scholar
• Huber-Lang MS, Sarma JV, McGuire SR, Lu KT, Padgaonkar VA, Younkin EM, Guo RF, Weber CH, Zuiderweg ER, Zetoune FS. Structure-function relationships of human C5a and C5aR. J Immunol. 2003;170(12):6115–24. doi:10.4049/jimmunol.170.12.6115. PMID:12794141
   PubMed Web of Science ®Google Scholar
• Vijayan S, Asare Y, Grommes J, Soehnlein O, Lutgens E, Shagdarsuren G, Togtokh A, Jacobs MJ, Fischer JW, Bernhagen J et al. High expression of C5L2 correlates with high proinflammatory cytokine expression in advanced human atherosclerotic plaques. Am J Pathol. 2014;184(7):2123–33. doi:10.1016/j.ajpath.2014.04.004. PMID:24819959
   PubMed Web of Science ®Google Scholar
• Hao J, Wang C, Yuan J, Chen M, Zhao MH. A pro-inflammatory role of C5L2 in C5a-primed neutrophils for ANCA-induced activation. PLoS One. 2013;8(6):e66305. doi:10.1371/journal.pone.0066305. PMID:23785491
   PubMed Web of Science ®Google Scholar
• Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256–64. doi:10.1038/nbt1344. PMID:17989688
   PubMed Web of Science ®Google Scholar
• Drogari-Apiranthitou M, Kuijper EJ, Dekker N, Dankert J. Complement activation and formation of the membrane attack complex on serogroup B Neisseria meningitidis in the presence or absence of serum bactericidal activity. Infect Immun. 2002;70(7):3752–8. doi:10.1128/IAI.70.7.3752-3758.2002. PMID:12065518
   PubMed Web of Science ®Google Scholar
• Riedemann NC, Habel M, Ziereisen J, Hermann M, Schneider C, Wehling C, Kirschfink M, Kentouche K, Guo R. Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition. Clin Immunol. 2017;180:25–32. doi:10.1016/j.clim.2017.03.012. PMID:28366510
   PubMed Web of Science ®Google Scholar
• Nandakumar KS, Jansson A, Xu B, Rydell N, Ahooghalandari P, Hellman L, Blom AM, Holmdahl R. A recombinant vaccine effectively induces c5a-specific neutralizing antibodies and prevents arthritis. PLoS One. 2010;5(10):e13511. doi:10.1371/journal.pone.0013511. PMID:20975959
   PubMed Web of Science ®Google Scholar
• Landlinger C, Oberleitner L, Gruber P, Noiges B, Yatsyk K, Santic R, Mandler M, Staffler G. Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer's disease. J Neuroinflammation. 2015;12:150. doi:10.1186/s12974-015-0369-6. PMID:26275910
   PubMed Web of Science ®Google Scholar
• Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol. 1996;14(3):309–14. doi:10.1038/nbt0396-309. PMID:9630891
   PubMed Web of Science ®Google Scholar
• Groves M, Lane S, Douthwaite J, Lowne D, Rees DG, Edwards B, Jackson RH. Affinity maturation of phage display antibody populations using ribosome display. J Immunol Methods. 2006;313(1-2):129–39. doi:10.1016/j.jim.2006.04.002. PMID:16730741
   PubMed Web of Science ®Google Scholar
• Lloyd C, Lowe D, Edwards B, Welsh F, Dilks T, Hardman C, Vaughan T. Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel. 2009;22(3):159–68. doi:10.1093/protein/gzn058. PMID:18974080
   PubMed Web of Science ®Google Scholar
• Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, Pedley B, Adair JR. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol. 1993;30(1):105–8. doi:10.1016/0161-5890(93)90432-B. PMID:8417368
   PubMed Web of Science ®Google Scholar
• Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther. 2007;7(9):1401–13. doi:10.1517/14712598.7.9.1401. PMID:17727329
   PubMed Web of Science ®Google Scholar
• Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. 5th Edition, US Department of Health and Human Services. Bethesda (MD): National Institutes for Health publication. 91--3242. 1991 p. 662,680,689.
   Google Scholar
• Fung M, Lu M, Fure H, Sun W, Sun C, Shi NY, Dou Y, Su J, Swanson X, Mollnes TE. Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage. Clin Exp Immunol. 2003;133(2):160–9. doi:10.1046/j.1365-2249.2003.02213.x. PMID:12869020
   PubMed Web of Science ®Google Scholar
• Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, Videm V, Lappegård KT, Köhl J, Lambris JD. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood. 2002;100(5):1869–77. PMID:12176911
   PubMed Web of Science ®Google Scholar
• Underhill DM, Ozinsky A. Phagocytosis of microbes: complexity in action. Annu Rev Immunol. 2002;20:825–52. doi:10.1146/annurev.immunol.20.103001.114744. PMID:11861619
   PubMed Web of Science ®Google Scholar
• Williamson MP, Madison VS. Three-dimensional structure of porcine C5adesArg from 1H nuclear magnetic resonance data. Biochemistry. 1990;29(12):2895–905. doi:10.1021/bi00464a002. PMID:2337573
   PubMed Web of Science ®Google Scholar
• Schatz-Jakobsen JA, Yatime L, Larsen C, Petersen SV, Klos A, Andersen GR. Structural and functional characterization of human and murine C5a anaphylatoxins. Acta Crystallogr D Biol Crystallogr. 2014;70(Pt 6):1704–17. doi:10.1107/S139900471400844X. PMID:24914981
   PubMedGoogle Scholar
• Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol. 1992;224(2):487–99. doi:10.1016/0022-2836(92)91010-M. PMID:1560463
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Tamerius JD, Chenoweth DE. Identification of an antigenic epitope and receptor binding domain of human C5a. J Immunol. 1987;138(11):3856–62. PMID:2438329
   PubMed Web of Science ®Google Scholar
• Kola A, Baensch M, Bautsch W, Hennecke M, Klos A, Casaretto M, Köhl J. Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis. Immuno Technol. 1996;2(2):115–26. doi:10.1016/1380-2933(96)00425-3.
   PubMedGoogle Scholar
• Guo R, Reidemann NC, Li Y, Shen B, inventors. Inflarx Gmbh, assignee. Anti-C5a binding antibodies with high block activity. United States Patent 8802096. 2014.
   Google Scholar
• Fung M, Lu M, Sun WNC, Sun CR, inventors. Genentech Inc., assignee. Anti-C5/C5a antibodies and methods of use. United States Patent 8372404. 2013.
   Google Scholar
• Siciliano SJ, Rollins TE, DeMartino J, Konteatis Z, Malkowitz L, Van Riper G, Bondy S, Rosen H, Springer MS. Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci U S A. 1994;91(4):1214–8. doi:10.1073/pnas.91.4.1214. PMID:8108389
   PubMed Web of Science ®Google Scholar
• Mollison KW, Mandecki W, Zuiderweg ER, Fayer L, Fey TA, Krause RA, Conway RG, Miller L, Edalji RP, Shallcross MA, et al. Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc Natl Acad Sci U S A. 1989;86(1):292–6. doi:10.1073/pnas.86.1.292. PMID:2643101
   PubMed Web of Science ®Google Scholar
• DeMartino JA, Van Riper G, Siciliano SJ, Molineaux CJ, Konteatis ZD, Rosen H, Springer MS. The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs. J Biol Chem. 1994;269(20):14446–50. PMID:8182049
   PubMed Web of Science ®Google Scholar
• Klos A, Wende E, Wareham KJ, Monk PN. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev. 2013;65(1):500–43. doi:10.1124/pr.111.005223. PMID:23383423
   PubMed Web of Science ®Google Scholar
• Otto M, Hawlisch H, Monk PN, Müller M, Klos A, Karp CL, Köhl J. C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. J Biol Chem. 2004;279(1):142–51. doi:10.1074/jbc.M310078200. PMID:14570896
   PubMed Web of Science ®Google Scholar
• Croker DE, Monk PN, Halai R, Kaeslin G, Schofield Z, Wu MC, Clark RJ, Blaskovich MA, Morikis D, Floudas CA et al. Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling. Immunol Cell Biol. 2016;94(8):787–95. doi:10.1038/icb.2016.43. PMID:27108698
   PubMed Web of Science ®Google Scholar
• Scola AM, Higginbottom A, Partridge LJ, Reid RC, Woodruff T, Taylor SM, Fairlie DP, Monk PN. The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding. J Biol Chem. 2007;282(6):3664–71. doi:10.1074/jbc.M609178200. PMID:17158873
   PubMed Web of Science ®Google Scholar
• Andersson C, Wenander CS, Usher PA, Hebsgaard JB, Sondergaard BC, Rønø B, Mackay C, Friedrichsen B, Chang C, Tang R et al. Rapid-onset clinical and mechanistic effects of anti-C5aR treatment in the mouse collagen-induced arthritis model. Clin Exp Immunol. 2014;177(1):219–33. doi:10.1111/cei.12338. PMID:24665841
   PubMed Web of Science ®Google Scholar
• Staab EB, Sanderson SD, Wells SM, Poole JA. Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthma. Int Immunopharmacol. 2014;21(2):293–300. doi:10.1016/j.intimp.2014.05.008. PMID:24859057
   PubMed Web of Science ®Google Scholar
• Rawal N, Pangburn MK. Formation of high affinity C5 convertase of the classical pathway of complement. J Biol Chem. 2003;278(40):38476–83. doi:10.1074/jbc.M307017200. PMID:12878586
   PubMed Web of Science ®Google Scholar
• Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62–73. doi:10.1111/bjh.12347. PMID:23617322
   PubMed Web of Science ®Google Scholar
• Gatault P, Brachet G, Ternant D, Degenne D, Récipon G, Barbet C, Gyan E, Gouilleux-Gruart V, Bordes C, Farrell A, et al. Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. MAbs. 2015;7(6):1205–11. doi:10.1080/19420862.2015.1086049. PMID:26337866
   PubMed Web of Science ®Google Scholar
• Janatova J. C3, C5 components and C3a, C4a, and C5a fragments of the complement system. Methods Enzymol. 1988;162:579–625. doi:10.1016/0076-6879(88)62104-5. PMID:3265757
   PubMed Web of Science ®Google Scholar
• Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol. 1992;226(3):889–96. doi:10.1016/0022-2836(92)90639-2. PMID:1507232
   PubMed Web of Science ®Google Scholar
• Dobson CL, Main S, Newton P, Chodorge M, Cadwallader K, Humphreys R, Albert V, Vaughan TJ, Minter RR, Edwards BM. Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism. MAbs. 2009;1(6):552–62. doi:10.4161/mabs.1.6.10057. PMID:20068388
   PubMed Web of Science ®Google Scholar
• Thompson J, Pope T, Tung JS, Chan C, Hollis G, Mark G, Johnson KS Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. J Mol Biol. 1996;256(1):77–88. doi:10.1006/jmbi.1996.0069. PMID:8609615
   PubMed Web of Science ®Google Scholar
• Persic L, Roberts A, Wilton J, Cattaneo A, Bradbury A, Hoogenboom HR. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene. 1997;187(1):1–8. doi:10.1016/S0378-1119(96)00627-010.1016/S0378-1119(96)00628-2. PMID:9073060
   PubMed Web of Science ®Google Scholar
• Choi KH, Gaynor JB, White KG, Lopez C, Bosio CM, Karkhoff-Schweizer RR, Schweizer HP. A Tn7-based broad-range bacterial cloning and expression system. Nat Methods. 2005;2(6):443–8. doi:10.1038/nmeth765. PMID:15908923
   PubMed Web of Science ®Google Scholar
• Paczkowski NJ, Finch AM, Whitmore JB, Short AJ, Wong AK, Monk PN, Cain SA, Fairlie DP, Taylor SM. Pharmacological characterization of antagonists of the C5a receptor. Br J Pharmacol. 1999;128(7):1461–6. doi:10.1038/sj.bjp.0702938. PMID:10602324
   PubMed Web of Science ®Google Scholar
• Leslie AG. The integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr. 2006;62(Pt 1):48–57. doi:10.1107/S0907444905039107. PMID:16369093
   PubMedGoogle Scholar
• Battye TG, Kontogiannis L, Johnson O, Powell HR, Leslie AG. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 4):271–81. doi:10.1107/S0907444910048675. PMID:21460445
   PubMedGoogle Scholar
• Evans P. Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr. 2006;62(Pt 1):72–82. doi:10.1107/S0907444905036693. PMID:16369096
   PubMedGoogle Scholar
• Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 4):235–42. doi:10.1107/S0907444910045749. PMID:21460441
   PubMedGoogle Scholar
• McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr. 2005;61(Pt 4):458–64. doi:10.1107/S0907444905001617. PMID:15805601
   PubMedGoogle Scholar
• Storoni LC, McCoy AJ, Read RJ. Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr. 2004;60(Pt 3):432–8. doi:10.1107/S0907444903028956. PMID:14993666
   PubMedGoogle Scholar
• Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 4):486–501. doi:10.1107/S0907444910007493. PMID:20383002
   PubMed Web of Science ®Google Scholar
• Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F, Vagin AA. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 4):355–67. doi:10.1107/S0907444911001314. PMID:21460454
   PubMed Web of Science ®Google Scholar